No CRS summary available for this bill.
This section states findings that human papillomavirus is the most common sexually transmitted infection in the United States, with a significant share of related oropharyngeal cancers occurring among men, and that no Food and Drug Administration-approved HPV diagnostic test exists for men. It further finds that this gap hinders surveillance and prevention, contributes to transmission affecting women’s health outcomes such as cervical cancer, and that coordinated strategies recommended in the National Academies of Sciences, Engineering, and Medicine 2023 report would advance gender equity in cancer control.
This section requires the Director of the National Institutes of Health to conduct a study, within 24 months of enactment, on the development of a standardized, noninvasive test for human papillomavirus in men, including assessments of current research gaps, multi-site testing approaches, pilot feasibility in diverse populations, and recommendations for regulatory approval and equitable access. It establishes an interagency working group with the Food and Drug Administration, Centers for Disease Control and Prevention, Health Resources and Services Administration, and National Academy of Medicine to coordinate implementation, and directs use of NIH appropriations for fiscal years 2026 through 2030.